The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Who are The Cancer Letter readers?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

After 45 years of covering oncology, we stopped and asked our readers: who are you?

In a survey sent out to The Cancer Letter’s weekly mailing list, we asked key questions about our readers, their professional degrees, their fields of interest, and their satisfaction with our coverage.

We were pleased to learn that you like us: 83.1% of you rated your satisfaction with our reporting of your areas of interest at a 4 or 5 out of 5, with an average score of 4.1 out of 5 (82%).

We sent the survey to a list of 6,000 readers, and received 419 responses (7%).

story1-1

Of the responses, 37.7% are MDs and 35.6% are PhDs. Within that list, 25 are MD PhDs (6%).

story1-2

*terminal degree

You identified yourselves primarily as clinicians (33.7%), basic scientists (27.2%), and administrators (30.3%)—a surprisingly balanced spread.

story1-3

While this survey didn’t include the thousands of readers at institutions that distribute the PDF internally, we were pleased to learn that you love reading our PDF edition as well as our online content. Redesigned in 2017, our PDF edition has won design awards, and is a primary way many of our readers access The Cancer Letter.

The Cancer Letter has over 200 institutional subscribers.
For login or subscription issues, inquiries about group rates, advertising, or any other administrative questions please contact katie@cancerletter.com.

story1-4

story1-5

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account